Asset profile

Rituximab

Monoclonal antibody

ApprovedUndisclosed / early pipelineCD20
Approvedregulatory verdict

Evidence outlook

Approved — Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (3)
August 2026 (1)
Phase 2Schizophrenia Spectrum and Other Psychotic DisordersActive not recruiting
Est. primary completion 2026-08-30 · NCT05622201 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)
Phase 2Secondary Progressive Multiple Sclerosis (SPMS)Recruiting
Est. primary completion 2026-09 · NCT06599307 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 1/2Crohn's DiseaseRecruiting
Est. primary completion 2026-12 · NCT00692939 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (3)
April 2027 (1)
Phase 2Psychosis, Autoimmune EncephalitisActive not recruiting
Est. primary completion 2027-04-30 · NCT03194815 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)
Phase 3Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS …Recruiting
Est. primary completion 2027-05 · NCT05834855 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-05-31 · NCT02727803 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (4)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)
Phase 2Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder, Brief Psychotic Disorder …Enrolling by invitation
Est. primary completion 2028-04-01 · NCT04323566 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)
Phase 2Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary HypertensionRecruiting
Est. primary completion 2028-08-01 · NCT03630211 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
October 2032 (1)
Phase 1/2SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4Recruiting
Est. primary completion 2032-10 · NCT05508009 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2037 (1)
July 2037 (1)
Phase 1/2Crohn DiseaseNot yet recruiting
Est. primary completion 2037-07 · NCT06986382 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.